Concepedia

Michael L. Salgaller

ML

Statistics

Publications

38

Citations

4.5K

H-Index

29

Active since

1985

Affiliations

National Cancer Institute(Current)

Northwest Biotherapeutics (United States)

Northwest Hospital

National Institutes of Health

Pacific Northwest Diabetes Research Institute

Michael L. Salgaller is an author at National Cancer Institute specializing in oncology, immunology, and cancer immunology.

Publications per year

1985–2016

38

Publications

38

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues

Maria R. Parkhurst, Michael L. Salgaller, Scott Southwood et al. · The Journal of Immunology · 1996 · 559 citations · Full text

Life Sciences, Immunology, Oncology +17

American Association for Cancer Research

Michael L. Salgaller · Expert Opinion on Investigational Drugs · 2000 · 474 citations

Life Sciences, Immunology, Oncology +17

Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.

Jeffrey S. Weber, Michael L. Salgaller, Dvorit Samid et al. · PubMed · 1994 · 296 citations

Life Sciences, Molecular Biology, Oncology +16

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

Licia Rivoltini, Yutaka Kawakami, Kazushige Sakaguchi et al. · The Journal of Immunology · 1995 · 294 citations

Life Sciences, Immunology, Oncology +17

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

Janice N. Cormier, Michael L. Salgaller, Tracy Prevette et al. · PubMed · 1997 · 277 citations

Life Sciences, Immunology, Oncology +17

1–5 of 38